Neurotrophic growth factors are involved in cell survival. However, natural growth factors have a very limited therapeutic use because of their short half-life. In the present study, we investigated the mechanism of action of a non peptidic neurotrophic drug, Xaliproden, a potential molecule for the treatment of motoneuron diseases, since the transduction pathways of this synthetic 5-HTIA agonist are very poorly understood. Xaliproden does not activate the Trk receptor but causes a rapid increase in the activities of the ERKl and ERK2 isoforms of MAP kinase, which then rapidly decrease to the basal level. We demonstrate that isoforms of the she adapter protein are phosphorylated independently of each other and are probably not the source of the Xaliproden-induced MAP kinases activation. The inhibitor of Ras farnesylation, FPT-l, and the protein kinase C inhibitors, GF l09203X and chelerythrine, inhibited the Xaliproden-induced MAP kinase activation, suggesting p21Ras and PKC involvement. Moreover, the observations that the 5-HTIA antagonist, pindobind, and pertussis toxin abolished theXaliproden-induced ERK stimulation suggested that Xaliproden activates the MAP kinase pathways by stimulating the Gprotein-coupled receptor, 5-HTIA. These results demonstrated clearly that the non peptidic compound, Xaliproden, exerts its neurotrophic effects through a mechanism of action differing from that of neurotrophins. These findings suggest that this compound does not involve MAPK activation by TrkA receptor stimulation but acts by MAP Kinase pathway by a pertussis toxin-sensitive mechanism involving 5-HTIA receptors, p21 Ras and MEK-l and by PKC and Akt pathways.
The most widely studied Trk-depending cascades are those of the TrkA-NGF activated signaling cascade, and more specifically that which involves she adapter protein. She binds to the juxtamembrane tyrosine 490 residue of the activated TrkA (8) after being phosphorylated by this kinase receptor (9) . Treatment of adequate neurons with NGF results in tyrosine phosphorylation of46 and 52 kD she proteins (p46 shc ; p52 ShC ) , and also of a minor and irregularly expressed isoform of she, namely the p66 shc encoded by a distinct transcript. The Trk-shc complex can bind the Grb2/Sos complex through the SH2 (srchomology) domain of Grb2 which is a phosphotyrosine recognition sequence (10) . Sos plays the role of an exchange factor, able to activate Ras (11). GTP-bound Ras activates then Rafkinases, Raf-1 and B-Raf. Activated Rafkinases phosphorylate and activate the mitogen activated protein (MAP) kinase kinase (MEK) which finally phosphorylate MAP kinases and especially ERKI and ERK2 (extracellular regulated kinases) on threonine 183 and tyrosine 185 (12) . In addition, G protein-coupled receptors (GPCRs) can activate the MAP kinases pathways (13) (14) . Cross talk between GPCRs and Trk is an incredibly complex process, and the exact signaling molecules involved are largely dependent on the cell type and the type of receptor that is activated (15) (16) . Independently ofthe pathway involved, MAP kinases, in combination with other signaling pathways, alter the phosphorylation status of transcription factors, so that a controlled regulation of MAP kinase activity allows cell proliferation and differentiation, whereas a dysregulation can lead to transformation.
Natural growth factors have a very short half-life and do not cross the blood-brain barrier. They often have a peripheral toxicity so that their therapeutic use is very limited. Some synthetic non peptide neurotrophic compounds have therefore been developed to replace them, bypassing these difficulties. Xaliproden (SR57746A) {1-[2-(naphtyl-2-yl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,5,6-tetrahydropyridine hydrochloride}, agonist of 5-hydroxytryptamine lA receptors (5-HTIA), has been shown to display a wide range of neurotrophic effects in vivo as well as in vitro (17) (18) . In vivo, it rescues motoneurons from death which regularly occurs after sciatic nerve section (19) and increases the mean survival time and motor performances of pmn mice which display an inherited axonopathy (20) . In vitro, it increases the promoting effects of NGF on neurite outgrowth of PC12 cells (21) and promotes the phenotypic survival of mouse purified motoneurons (22) . However, the mechanism of action of this compound remains little understood.
We present results here showing that Xaliproden is unable to activate TrkA ofPCl2 cells -which were chosen because they express high amounts of this receptor and have been widely used as a model system for studying the Trk-dependent signaling cascade -but acts in such a way as to phosphorylate she adapter protein, and ERKl, ERK2, via MAP kinase kinase (MEK). We demonstrate that Xaliproden activates ERK by a pertussis toxin-sensitive mechanism involving the 5-HTIA receptors, the p21 Ras, the protein kinase C (PKC) and MEK-l. On the other hand, Xaliproden stimulates Akt activity, an another pathway implicated in cell survival.
MATERIALS AND METHODS

Chemicals and reagents
Anti-Trk (C-14) antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-she and anti-phosphotyrosine monoc1onal4G I0 antibodies were from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Anti-ACTIVE MAP kinase antibody was from Promega Corporation (Madison, WI, USA). Anti-5-HTIA receptor was from Chemicon (Temecula, CA, USA). AntiphosphoPKC (pan) was from Cellular Signaling (Beverly, MA, USA). Anti-phospho Akt and anti-Akt were from New England Biolabs (Beverly, MA, USA). Anti-actin was from Sigma (L'Isle d' Abeau-Chesnes, France). Fluoresceinlabeled anti-guinea pig IgG was from Euromedex (Souffelweyersheim, France). NGF was from PeproTech Inc. (Rocky Hill, NJ, USA). Pindobind, 8-0H-DPAT, protease inhibitors, sodium orthovanadate, protein A sepharose (CL-4B) and goat anti-rabbit IgG FITC-conjugate were from Sigma. PD98059 was provided from Calbiochem (Darmstadt, Germany). GF109203X was from Alexis Biochemicals (Shelton, CT, USA). Chelerythrine chloride was from Euromedex. Pertussis toxin was from Interchim (Montlucon, France). The enhanced chemoluminescence (ECL) detection system was purchased from Amersham (Amersham France SA, Les Ulis, France). RPMI 1640 and fetal calf serum (FCS) were provided by Gibco (Life Technologies, Cergy-Pontoise, France). Nu-serum culture supplement was purchased from Becton Dickinson (Bedford, MA, USA). Xaliproden (Sanofi-Synthelabo Recherche, Montpellier, France) (Molecular weight: 417.90) was dissolved in dimethyl sulfoxide (DMSO) (Sigma), then diluted in culture medium and added to the cells at a final concentration of I flM.
Cell culture PC12 rat pheochromocytoma cells were a generous gift from Dr. Jean Zwiller (Centre de Neurochimie, Strasbourg, France). Cells were maintained as monolayer cultures in 75-em' culture flasks (Gibco) in RPMI 1640 medium containing 10% of a mixture of Nu-serum (1 volume) and FCS (2 volumes) and 1 % of a mixture of antibiotics (Gibco); they were incubated at 37°C in a 5% CO 2 humidified atmosphere. The medium was changed every two days. Cells were incubated for varying times with Xaliproden ranging from 100 nM to 5 flM, 100 ng/ml NGF or 0.02% DMSO (control). Cells were pre-incubated with or without PD 98059 (1 flM, 5 flM and 10 flM, 30 min), GF109203X (1 flM, Ih), Chelerythrine Chloride (1flM, Ih), Pindobind (10 flM, 1h) or pertussis toxin (50 ng/m1, 2h). Then, Xa1iproden at 1 flM was added for 5 min. Cells were incubated with 8-0H-DPAT at 250 nM, 500 nM and 1 mM for 5 min.
Preparation oftotal cell extracts
After incubation under different experimental conditions, cells were washed twice with ice-cold phosphate-buffered saline (PBS) and harvested in lysis buffer (20 mM Tris pH 8, 137 mM sodium chloride, 1% Nonidet P-40, 10% glycerol, 50 mM sodium fluoride, 10 mM sodium pyrophosphate) supplemented with 1eupeptin (5 ug/ml), antipain (5 ug/ml), chymostatin (5 ug/ml), aprotinin (5 ug/ml), E64 (1 mgll) and sodium orthovanadate (5 mM). Cell Iysates were cleared by centrifugation at 16,000 x g for 10 min. The proteins in total Iysates were assayed before immunoprecipitation or polyacrylamide gel electrophoresis (PAGE). Measurements were done using a micro BCA kit (Pierce, Rockland, IL, USA) with BSA as a standard.
Immunoprecipitation ofTrk or she Extracts were immunoprecipitated with either anti-Trk or anti-she. Controls were not treated with antibody. Immunoprecipitation assays were performed by incubating the celllysates (800 ug) overnight at +4°C with the antiTrk antibody diluted to 1:50 or with anti-she antibody diluted to 1:1000. Then, 10 mg of protein A sepharose beads (Sigma) in lysis buffer, preincubated overnight with a 10% BSA solution in lysis buffer, were added to the extracts and placed for 2 h under continuous rotation at +4°C.
Immunoprecipitates were collected by centrifugation (5,000 x g) for 5 min at +4°C, and washed twice with lysis buffer, twice with I M lithium chloride (Sigma) in 20 mM Tris, pH 7, and twice with 20 mM Tris, pH 7. Washed beads were resuspended in reducing Laemmli buffer and boiled for 5 min. Proteins were then size-fractionated on a 7% SDS-polyacrylamide gel. The gels were transferred onto nitrocellulose membrane and the blots were blocked for 30 min by dipping in PBS containing 5% non-fat milk (PBS/MLK) and then incubated overnight at +4°C with anti-phosphotyrosine at a I :500 dilution. The blots were washed twice with distilled water and incubated with peroxidase-labeled antimouse IgG antibody (Amersham ECL Kit) at a 1:10,000 dilution in PBS-MLK for 1 h 30, followed by visualization with ECL substrate (Amersham). Blots were analyzed using NIH image 1.61/ppc software (National Institutes of Health, Bethesda, MD, USA). To reprobe the blots, the membrane was stripped for 30 min in 62.5 mM Tris-HCI buffer, pH 6.7, containing 2% of SDS and 10 mM bmercaptoethanol, blocked, and reprobed with the control antibody (Anti-Trk antibody).
Immunoblotting with anti-MAP KINASE antibody
An aliquot of protein (30 ug) was applied to a 10% SDS-PAGE. After being transferred onto nitrocellulose membrane (Amersham), blots were blocked overnight with a 1% BSA solution in TBS (Tris HCI pH 8, 0.138 M NaCl) and then incubated for 1 h 30 with the anti-ACTIVE MAP kinase antibody diluted to I :5,000 in TBST (Tris HC1 pH 8, 0.138 M NaCl, 0.05% Tween 20) supplemented with 0.1% BSA. The blots were washed three times in TBST and were incubated with peroxidase-labeled antirabbit IgG antibody (Amersham ECL kit) diluted to 1:30,000 dilution in TBST for 1 h. The bands were visualized using ECL Western blotting detection kit by exposure to X-ray films (RPN2103H from Amersham). To reprobe the blots, the membrane was stripped for 15 min in Restore Western Blot buffer (Pierce) blocked, and reprobed with the control antibody (anti-actin antibody).
Immunoblotting with anti-phosphoPKC (pan) antibody
An aliquot of protein (30 ug) was applied to a 10% SDS-PAGE. After being transferred onto nitrocellulose membrane (Amersham), blots were blocked overnight with a 3% BSA solution in TBS and then incubated for I h with the anti-phospho PKC (pan) antibody diluted to I: I,000 in TBST supplemented with 0.1% BSA. The blots were washed three times in TBST and were incubated with peroxidase-labeled anti-rabbit IgG antibody diluted to I :30,000 dilution in TBST for I h. The bands were visualized using ECL Western blotting detection kit by exposure to X-ray films. To reprobe the blots, the membrane was stripped for 15 min in Restore Western Blot buffer blocked, and reprobed with the control antibody (anti-actin antibody).
RESULTS
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and 48 h to be maximal (Fig. 2B) . TrkA underwent a heavy phosphorylation upon exposure of PC 12 cells to NGF ( 100 ng/ml), whereas Xaliproden (1 JlM ) applied for 5 to 30 min did not induce phosphorylation ofthis receptor (Fig. lA) . The same observations were obtained with 10 JlM of Xaliproden (data not shown). When combined with NGF, Xaliproden did not alter the phosphorylation level ofTrkA by NGF (Fig. IB) .
She stimula tion by Xaliproden .
Lysates from PC12 cells exposed to NGF (100 ng/ml) for 5 min or to Xaliproden ( I JlM) for 5 min, 24 h or 48 h were studied for their content in phosphorylated she adapter protein. Fig. 2A shows that the phosphorylation of p66 shc was already detectable after 5 min of treatment with both drugs, and reached its maximum at that time . In the prese nce of Xaliproden, it remained stable for 24 h and then progressively decreased. It took 24 h for the phosphorylation of p52 shc isoform began to be visible The Xaliproden-dependent activation ofERKl and ERK2.
As expected, exposure of PC 12 cells to NGF (100 ng/ml) for 5 min resulted in activation of ERKI and ERK2 MAP kinases. Xaliproden was also able to activate these kinases in a dose-dependent manner, with an optimal concentration of 5 mM ofXaliproden (Fig. 3A) . Moreover, activation of both enzymes was maximal after 5 min of treatment (3-fold increase) and then quickly returned to basal levels within 10 min (Fig.3B) .
Pathway of Xalip roden to activate ERKl and ERK2 .
In order to determine whether the MAP kinase kinase (MEK) is involved in the activation of ERK 1 and ERK2, PC 12 cells were exposed to Xaliproden (1 JlM) A. Xaliproden (Fig. 4) as compared to DMSO 0.02%. At higher doses, PD 98059 could inhibit completely the activation ofERKs. As MEK is downstream of PKC, we examined if this pathway is implicated in the effect of Xaliproden on ERK phosphorylation. A pretreatment with a selective inhibitor of PKC, the Che1erytrine chloride (l mM, lh) blocked the activation ofERK 1/2 induced by Xaliproden supporting an active role ofPKC in the phosphorylation of ERK 1/2 induced by Xaliproden (Fig. 5A) . GFI09203X, another PKC inhibitor repressed also the activation of MAP kinase induced by Xaliproden (data not shown). Therefore, to determine whether xaliproden impacted PKC activation, western analysis was performed using a phosphoPKC antibody to isoforms a,~I,~II, "{, O. In PCI2 cells, Xaliproden induced PKC phosphorylation at 30 min (Data not shown). Xaliproden is an agonist of 5-HTlA receptors and these receptors has been reported to activate MAP kinase by PKC activation. The treatment of PCI2 cells with pindobind, an antagonist of 5-HT IA receptors, at 10 flM for 5min, inhibited PKC activation induced by Xaliproden as compared to DMSO 0.02% (Fig. 5B) . The treatment of PC 12 cells with the bacterial toxin, pertussis toxin (which inactivates the G protein G i/o ) at 50 ng/ml for 2h inhibited like pindobind , the Xaliproden-dependent activation of PKC (Fig . 58) . The treatment of PC 12 cells with pindobind at the same concentrations as previously, also inhibited the Xaliproden-dependent activation ofERK 1/2 (Fig. 6A) . The same results are obtained with pertussis toxin (Data not shown) .
. Xaliproden induces activation ofERK1 and ERK2 in PC12 cells. Whole celllysates (30 f.lg) were separated by SDS-PAGE (10%) and immunoblotted (Blot) with the anti-ACTIVE MAP kinase antibody as described in Materials and Methods. The same blot was stripped and reprobed with control antibody (anti-actin
. Inhibition ofMEK impairs Xaliproden induced-MAP kinase activation. Whole celllysates (30 mg) were separated by SDS-PAGE (10%) and immunoblotted with the anti-ACTIVE MAP kinase antibody as described in Materials and Methods. The same blot was stripped and reprobed with control antibody (antiactin
Therefore, taken together, these results suggest that Xaliproden-dependent activation of ERK 1/2 result from its binding to 5-HTIA receptors. To confirm this hypothesis, we use an agonist of 5-HTIA receptor, 8-OH-DPAT to observe whether it allows ERK I and ERK2 activation. The treatment of PC 12 cells with 8-OH-DPAT (0.25-1 IJ,M) for 5 min stimulated p42/p44 MAP kinase activation in a dose dependent manner in the same order that NGF (100 ng/ml) (Fig. 68) . Moreover, we verified the presence of 5-HTIA receptors in PC 12 cells by immunocytochemistry (Data not shown) .
DISCUSSION
Neurotrophins and related growth factors induced cell survival and growth of numerous neurons, by activating Trk receptor kinases. Pradines et al. (21) suggested that Xaliproden, a neurotrophic synthetic compound, exerted its action by this pathway. Howe ver, since Xaliproden does not induce autophosphorylation of TrkA in PC I2 cells , it is difficult to attribute its neurotrophic properties to a direct effect on these receptors . Xaliproden obviously exerts its neurotrophic action through a mechanism of action differing from that of NGF. This conclusion is supported by the fact that Xaliproden promotes survival and differentiation of cultured motoneurons (22) which do not express trkA whereas NGF is devoid of any effect of these cells. In the signal transduction pathway stimulated by neurotrophic growth factors, the she adapter proteins are located immediately downstream the Trk receptor and upstream of the A. MAP kinases . Since upon exposure of PC 12 cells to Xaliproden, the optimal phosphorylation level of ERKI and ERK2 is reached before the optimal phosphorylation level ofp52 shc , one cannot conclude that Xaliproden induces a direct tyrosine phosphorylation of she through an unknown mechanism and stimulates the Trk-dependent signaling pathway right downstream of the tyrosine kinase receptor itself. Therefore, the phosphorylation of she appears to be the consequence of ERKI and ERK2 activation. The question of whether tyrosine phosphorylation ofp52'h<: and p66'hCcould be due to an activation of MAP kinases is still open.
The kinetics of activation and inactivation of components participating in the ERK I and ERK2 pathway can govern the extent and duration of effects of these MAP kinases and determine the cellular response to a given stimulus (23) . In PCl2 cells , the duration ofERKI/ERK2 signal is a critical factor in the decision of cells to differentiate or to grow. A prolonged activation leads to cell differentiation, whereas a transient activation results in cell growth (26) and promotes therefore cell survival (27) (28) . However, as the inhibition of MEK abrogates completely the neuroprotective effect of Xaliproden, we can exclude that the signal transducer and activator of transcription family is involved in the effect of this compound on mouse purified motoneurons.
The present results show also that ERK activation is sensitive to PKC inhibitors like GF 109203X and chelerythrine chloride and to pindobind (antagonizing the 5-HTlA receptor) and pertussis toxin (uncoupling the G-protein-coupled receptors and G protein), both desactivating 5-HTlA receptors.
Moreover, Xaliproden can activate PKC and this activation is sensitive to pindobind and pertussis toxin. Collectively, these data indicate that Xaliproden activates MAP kinase via ERK pathway and PKC through the G protein coupled 5-HTlA receptor activation.
Several groups have shown that the 5-HTlA receptor activates ERK MAP KINASE in CHO cells (29) (30) . Such stimulation has been reported to inhibit apoptosis in neuronal cells (31) (32) . Adayev et al. (31) have shown that the 8-0H-DPAT-mediated protection of neuronal HN2-5 cells resulted from a stimulation of the Ras-Raf-1-MEK-ERK pathway probably through PLCb activation. Furthermore, activation ofPKC by 5-HTlA receptor depends upon PLC activation by G protein bg subunits (33) . We have shown in our model that 8-0H-DPAT was able to activate ERKI and ERK2 in the same conditions as Xaliproden.
Several reports have shown that the activation of MAP kinases induced by G protein bg subunits is mediated by a common signaling pathway with receptor tyrosine kinases. The data reported in these studies suggest that activation of MAP kinases by Giprotein-coupled receptors is preceded by Gbgmediated tyrosine phosphrylation of she, leading to an increased fuctionnal association between She, Grb2, and Sos (34) .
In addition to Ras-ERK pathway, PI3K-Akt pathway is another well established survival signaling pathway. Akt promotes survival at multiple levels by inactivating components ofthe apoptotic machinery, by inhibiting transcription ofdeath genes, and by inducing expression of survival genes (35) . Xaliproden activates Akt in an extended manner that could be important in SR57746A neuroprotective effect (Data not shown). In conclusion, we demonstrated that Xaliproden activates PKC and ERK kinases not by trkA activation but by a pertussis toxin-sensitive mechanism involving the 5-HT 1A receptors, the p21 Ras and MEK-1.
